SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...
Morning Overview on MSN
New study flags powerful drug target that could transform glaucoma treatment
Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...
Clinicians seem to generally use intraocular pressure (IOP) as a continuous risk factor in their treatment patterns in ...
The authors noted that this is the first prospective case series to apply a structured, protocol-based approach to ...
Fluctuations in blood pressure over an extended period, along with their interaction with mean blood pressure or intraocular pressure, are associated with a more rapid visual field progression in ...
Shuchi Patel, MD: Good afternoon, Dr. Ruth Williams. Thank you so much for taking the time to have a discussion with us regarding a topic that is of emerging interest. Today we're going to talk about ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback